Showing 2021-2030 of 2657 results for "".
- Research Unveils Potential Breakthrough in Diabetic Retinopathy Treatmenthttps://modernod.com/news/research-unveils-potential-breakthrough-in-diabetic-retinopathy-treatment/2481962/Researchers from Washington University in St. Louis have discovered a potential new treatment approach to diabetic retinopathy. Diabetic retinopathy’s enigma unfolds with the role of microglia, immune cells resident in the retina. When confronted with high blood glucose levels, th
- World’s First Whole Eye & Partial Face Transplant Performed at NYU Langone Healthhttps://modernod.com/news/worlds-first-whole-eye-partial-face-transplant-performed-at-nyu-langone-health/2481958/A surgical team from NYU Langone Health performed the world’s first whole-eye and partial-face transplant for a 46-year-old military veteran from Arkansas who survived a work-related high-voltage electrical accident. The surgery included transplanting the entire left eye and a portion of th
- Alcon Canada Launches Clareon Vivity, its Latest Advancement in Presbyopia Correcting IOLshttps://modernod.com/news/alcon-canada-launches-clareon-vivity-its-latest-advancement-in-presbyopia-correcting-iols/2481956/Alcon announced that Clareon Vivity, the first and only non-diffractive extended depth of focus (EDOF) IOL on Alcon’s lens platform, is now available in Canada. [1-6] Clareon Vivity is designed to provide high-quality vision from distance to functional near with a visual dist
- Kiora’s KIO-301 Molecular Photoswitch Evaluated for Retinitis Pigmentosa in ABACUShttps://modernod.com/news/kioras-kio-301-molecular-photoswitch-evaluated-for-retinitis-pigmentosa-in-abacus/2481946/Kiora Pharmaceuticals announced topline results of a phase 1/2 clinical trial demonstrating proof-of-concept that KIO-301, the company’s first-in-class intravitreal (IVT) molecular photoswitch, has the potential to meaningfully improve vision in patients with retinitis pigmentosa (RP)
- ADA and Genentech Launch Campaign to Raise Awareness and Address Inequity in Diabetes-Related Eye Diseasehttps://modernod.com/news/ada-and-genentech-launch-campaign-to-raise-awareness-and-address-inequity-in-diabetes-related-eye-disease/2481933/The American Diabetes Association (ADA) and Genentech, anchor partner of the ADA’s 'Health Equity Now' program, launched the 'Eye Pledge to Fight Diabetes.' This program encourages people with diabetes and their loved ones to get an annual eye exam, which have
- Centricity Vision Announces Commercial Launch of ZEPTOLink IOL Positioning System at AAOhttps://modernod.com/news/centricity-vision-announces-commercial-launch-of-zeptolink-iol-positioning-system-at-aao/2481931/Centricity Vision announced the commercial launch of its ZEPTOLink IOL Positioning System at the American Academy of Ophthalmology (AAO) annual meeting, November 3-6 in San Francisco. The new platform integrates the ZEPTO precision pulse capsulotomy technology with any phaco s
- Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for its First Pivotal Clinical Trial of OTX-TKI in Wet AMDhttps://modernod.com/news/ocular-therapeutix-receives-fda-agreement-under-special-protocol-assessment-spa-for-its-first-pivotal-clinical-trial-of-otx-tki-in-wet-amd/2481928/Ocular Therapeutix announced it has received written agreement regarding the overall design from the FDA under a Special Protocol Assessment (SPA) for the company’s ongoing pivotal phase 3 clinical trial for Axpaxli (axitinib intravitreal implant), for the treatment of wet ag
- Ocuphire Pharma Announces Appointment of George Magrath, MD, MS, as Chief Executive Officer and Directorhttps://modernod.com/news/ocuphire-pharma-announces-appointment-of-george-magrath-md-ms-as-chief-executive-officer-and-director/2481927/Ocuphire Pharma announced the appointment of George Magrath, MD, MS, as Chief Executive Officer and member of the Board of Directors, effective today. Dr. Magrath succeeds Rick Rodgers, Interim CEO and President since April 2023. Mr. Rodgers will remain on the company’s Board of Direct
- ViaLase Completes Enrollment for the VIA-002 Trial of the ViaLase Laser to Treat Primary Open Angle Glaucomahttps://modernod.com/news/vialase-completes-enrollment-for-the-via-002-trial-of-the-vialase-laser-to-treat-primary-open-angle-glaucoma/2481921/ViaLase announced it has completed enrollment of VIA-002, the company's pivotal trial of the ViaLase Laser to treat adult patients with primary open angle glaucoma (POAG). The ViaLase Laser combines the precision of femtosecond laser technology and the accuracy of micron-level image
- FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)https://modernod.com/news/fda-approves-genentechs-vabysmo-for-the-treatment-of-retinal-vein-occlusion-rvo/2481917/The FDA has approved Genentech's Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). The approval for RVO marks the third indication for Vabysmo, along with wet age-related macular degeneration (AMD) and diabetic macular edem